Ask AI
ProCE Banner Activity

Discordant Guidelines: To Treat or Not to Treat HCV During Pregnancy?

Clinical Thought

In recent years, the burden of hepatitis C virus (HCV) infection has shifted toward younger populations, including pregnant people. However, infectious disease and obstetrics guidelines are split on whether pregnant people with HCV should be treated during pregnancy or postpartum. Keep reading to learn when I believe pregnant people should be treated for HCV to optimize their odds for retention in care and prevention of perinatal transmission.

Released: November 20, 2026

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education in partnership with the American Liver Foundation.

ProCE Banner

Supporters

This activity is supported by an educational grant from Gilead Sciences, Inc.

Gilead Sciences, Inc.

Partners

American Liver Foundation

ProCE Banner

Target Audience

This activity is intended for physicians, nurse practitioners, physician associates, pharmacists, nurses, and other HCPs who practice in primary care, infectious diseases (ID), gastroenterology (GI)/hepatology, obstetrics/gynecology (OB/GYN), addiction medicine, and other specialty and non-specialty settings who are involved in the screening, treatment, and care of individuals at risk for or living with HBV and/or HCV. 

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Integrate optimal screening strategies for HBV and HCV into clinical workflows across diverse care settings

  • Adjust strategies for screening and management of pregnant individuals with HBV and HCV based on current guidelines and emerging data

  • Apply simplified approaches for HBV and HCV treatment in specialty and non-specialty settings

  • Develop evidence-based strategies to improve patient engagement with viral hepatitis care through effective shared decision-making, stigma reduction, and care navigation

Financial Disclosures

Primary Author

Catherine Chappell, MD, MSc: consultant/advisor/speaker: Gilead; researcher: Gilead, Merck.